Anavex Life Sciences Corp (OTCMKTS:AVXL) is optimistic after it came across the findings of a new report published in peer-reviewed journal Neuroscience Letters. It states that microglial inflammation involved in devastating neurodegenerative diseases can be treated by sigma-1 receptor activation. It has been done through real-time in vivo imaging.

The role

Anavex said that sigma-1 receptor activation plays an important role in reducing the negative reactions rooted from chronic microglia over-activation. The problem kills the cells and results in multiple neurodegenerative diseases. It can be anything from brain injury to severe Alzheimer’s disease. The immune cells of the CNS are termed as Microglia and when a person gets a brain injury these cells enter the damaged region and clear it by engulfing dying neurons.

The problem

Here, it is important to understand that these immune cells can also create problems. In context of several neurological disorders, the cells responses are exaggerated and leads to neurode generation. The trial sums up that the sigma-1 receptor efficiently helps to control this damaging chronic microglial response. Additionally, the response of the sigma-1 receptor on immune cells was found to be specific to control responses as it did not hampered the normal microglia activity within the brain.

Positive findings

The data was considered as positive by Anavex Life Sciences as it confirms the therapeutic impact of sigma-1 receptor agonists. The company’s candidate ANAVEX 2-73 is in a Phase 2a clinical study for treatment of Alzheimer’s disease. Christopher U. Missling, PhD, the CEO said that results published in journal indicated that increasing sigma-1 receptor response through agonists could mitigate the harmful influence of neuroinflammation and blown up microglial response.

In last trading session, the stock price of Anavex Life Sciences surged more than 21% to close the trading session at $0.325. The share volume was 1.98 million compared to the average volume of 899,216.

Previous articleAVRA Inc (OTCBB:AVRN) Hires SightSpan as Global Risk, Compliance And Security Consultants
Next articlePositiveID Corp (OTCMKTS:PSID) Concludes Phase II Assessment Of Firefly Dx PCR
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.